Abstract P51 Table 1

Clinical effectiveness of procalcitonin-based protocols to initiate or discontinue antibiotics in patients presenting with acute exacerbations of COPD

OutcomesNo of participants
(studies)
Follow-up
Quality of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects
Risk with standard careRisk difference with Procalcitonin-guided protocols
Treatment failure for the index exacerbation.834
(5 RCTs)
⊕⊕○○
LOW 1,2
RR 0.81
(0.62 to 1.06)
206 per 1,00039 fewer failures per 1,000
(78 fewer to 12 more)
Length of hospital stay for the index exacerbation1062
(8 RCTs)
⊕⊕⊕○
MODERATE 1
MD −0.76(−1.95 to 0.43)Mean length of hospital stay was 8.55 daysMD 0.76 days lower
(1.95 lower to 0.43 higher)
Proportion of patients who were prescribed antibiotics on admission984
(7 RCTs)
⊕⊕⊕○
MODERATE 1
RR 0.56
(0.43 to 0.73)
791 per 1,000348 fewer prescriptions per 1,000
(451 fewer to 214 fewer)
Mean duration of the course of antibiotics776
(6 RCTs)
⊕⊕○○
LOW 1,2
MD −3.83
(−4.32 to −3.35)
Mean duration of course of antibiotics was 8.27 daysMD 3.83 days lower
(4.32 lower to 3.35 lower)
Exacerbation recurrence rate at longest follow-up496
(3 RCTs)
⊕⊕○○
LOW 1,2
RR 0.96
(0.69 to 1.35)
205 per 1,0008 fewer recurrences per 1,000
(63 fewer to 72 more)
Re-hospitalisation rate at longest follow-up398
(3 RCTs)
⊕⊕○○
LOW 1,2
RR 1.45
(0.92 to 2.29)
116 per 1,00052 more admissions per 1,000
(9 fewer to 150 more)
Rate of re-hospitalisation due to an exacerbation at longest follow up298
(2 RCTs)
⊕⊕○○
LOW 1,2
RR 1.22
(0.71 to 2.09)
135 per 1,00030 more admissions per 1,000
(39 fewer to 147 more)
Overall mortality at longest follow up1062
(8 RCTs)
⊕⊕○○
LOW 1,2
RR 0.99
(0.57 to 1.70)
41 per 1,0000 fewer deaths per 1,000
(18 fewer to 29 more)
  • *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; MD: Mean difference.